RxDoctor Payments Data

Precious Macauley, MD

Pulmonary Disease · Memphis, TNNPI 1952784266

Payments from drug & device makers

$1,569in general payments, 2019–2025

Across 74 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$212
  • GSK$192
  • Regeneron Healthcare Solutions, Inc.$164
  • United Therapeutics Corporation$151
  • Abiomed$122
  • Merck$110
  • plus $617 from 16 others

What the payments were for

  • Food & beverage$1,54198%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,569 in reported general payments places this provider in the 35th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$171,937
Medicare patients
564
Services billed
1,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate19$243,598
Trelegy ElliptaFluticasone/Umeclidin/Vilanter110$88,247
NucalaMepolizumab12$41,610
Spiriva RespimatTiotropium Bromide42$27,728
Breo ElliptaFluticasone/Vilanterol35$14,517
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,452
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,533
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,855
DuleraMometasone/Formoterol13$3,648
SymbicortBudesonide/Formoterol Fumarate15$3,367
Mycophenolate Mofetil30$2,403
Albuterol Sulfate HfaAlbuterol Sulfate67$1,693
Ventolin HfaAlbuterol Sulfate13$817
Wixela InhubFluticasone Propion/Salmeterol12$792
Fluticasone Propionate58$634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$50$276,85873 claims
GSKTrelegy Ellipta, Nucala, Breo Ellipta$192$144,374157 claims
AstraZenecaBreztri Aerosphere, Symbicort$212$15,81934 claims
MerckDulera$110$3,64813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →